➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: October 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,649,352

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,649,352 protect, and when does it expire?

Patent 9,649,352 protects ORBACTIV and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 9,649,352
Title:High purity oritavancin and method of producing same
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Inventor(s): Rafai Far; Adel (Mount-Royal, CA), Krishna; Gopal (Parsippany, NJ), Ding; Min (Parsippany, NJ), Chemburkar; Sanjay R. (North Chicago, IL), Knable; Carl M. (North Chicago, IL), Petzel; James P. (North Chicago, IL), Pruyne; Julie J. (North Chicago, IL), Reamer; Douglas M. (North Chicago, IL)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ) ABBVIE INC. (Chicago, IL)
Application Number:14/801,303
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,649,352

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.